The Latin America, Middle East and Africa Theranostics Market would witness market growth of 18.3% CAGR during the forecast period (2023-2030).
The Brazil market dominated the LAMEA Theranostics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $95.9 million by 2030. The Argentina market is showcasing a CAGR of 19% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 18% during (2023 - 2030).
Targeted therapies, including antiviral drugs, antibiotics, and immunomodulatory agents, deliver precise treatments tailored to the specific pathogens and host responses, improving clinical outcomes and reducing the spread of drug-resistant infections. Moreover, theranostics facilitate real-time monitoring and assessment of treatment response by providing quantitative and qualitative measures of disease progression and therapeutic efficacy.
Imaging techniques such as PET/CT, MRI, and ultrasound monitor changes in tumor size, metabolic activity, and perfusion dynamics, enabling early detection of treatment response or resistance. Molecular biomarkers, including circulating tumor DNA (ctDNA), tumor markers, and immune markers, assess treatment response at the molecular level, guiding adjustments to treatment regimens and therapeutic interventions.
The expansion of the healthcare sector in Saudi Arabia leads to improved access to healthcare services for the population, including advanced diagnostic and therapeutic technologies such as theranostics. According to the International Trade Administration data, Saudi Arabia contributes 60% of the healthcare expenditures of the Gulf Cooperation Council (GCC) nations, and the Saudi Arabian government continues to prioritize this sector. Thus, the expansion of the region’s healthcare sector is propelling the market’s growth.
Based on End User, the market is segmented into Hospitals & Cancer Care Centers, Theranostics Centers, and Research & Academic Centers. Based on Product, the market is segmented into Radiopharmaceuticals, Diagnostic Imaging, IVD/Biomarker Screening, and Software & Services. Based on Application, the market is segmented into Prostate Cancer, Bone Metastasis, Other Cancers, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Theranostics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $95.9 million by 2030. The Argentina market is showcasing a CAGR of 19% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 18% during (2023 - 2030).
Targeted therapies, including antiviral drugs, antibiotics, and immunomodulatory agents, deliver precise treatments tailored to the specific pathogens and host responses, improving clinical outcomes and reducing the spread of drug-resistant infections. Moreover, theranostics facilitate real-time monitoring and assessment of treatment response by providing quantitative and qualitative measures of disease progression and therapeutic efficacy.
Imaging techniques such as PET/CT, MRI, and ultrasound monitor changes in tumor size, metabolic activity, and perfusion dynamics, enabling early detection of treatment response or resistance. Molecular biomarkers, including circulating tumor DNA (ctDNA), tumor markers, and immune markers, assess treatment response at the molecular level, guiding adjustments to treatment regimens and therapeutic interventions.
The expansion of the healthcare sector in Saudi Arabia leads to improved access to healthcare services for the population, including advanced diagnostic and therapeutic technologies such as theranostics. According to the International Trade Administration data, Saudi Arabia contributes 60% of the healthcare expenditures of the Gulf Cooperation Council (GCC) nations, and the Saudi Arabian government continues to prioritize this sector. Thus, the expansion of the region’s healthcare sector is propelling the market’s growth.
Based on End User, the market is segmented into Hospitals & Cancer Care Centers, Theranostics Centers, and Research & Academic Centers. Based on Product, the market is segmented into Radiopharmaceuticals, Diagnostic Imaging, IVD/Biomarker Screening, and Software & Services. Based on Application, the market is segmented into Prostate Cancer, Bone Metastasis, Other Cancers, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Bayer AG
- GE HealthCare Technologies, Inc.
- Siemens Healthineers AG (Siemens AG)
- Cardinal Health, Inc.
- Canon, Inc.
- Clarity Pharmaceuticals Ltd
- Koninklijke Philips N.V.
- Thermo Fisher Scientific, Inc.
- Telix Pharmaceuticals Limited
- ABX advanced biochemical compounds GmbH
Market Report Segmentation
By End User- Hospitals & Cancer Care Centers
- Theranostics Centers
- Research & Academic Centers
- Radiopharmaceuticals
- Diagnostic Imaging
- IVD/Biomarker Screening
- Software & Services
- Prostate Cancer
- Bone Metastasis
- Other Cancers
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Theranostics Market by End User
Chapter 5. LAMEA Theranostics Market by Product
Chapter 6. LAMEA Theranostics Market by Application
Chapter 7. LAMEA Theranostics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bayer AG
- GE HealthCare Technologies, Inc.
- Siemens Healthineers AG (Siemens AG)
- Cardinal Health, Inc.
- Canon, Inc.
- Clarity Pharmaceuticals Ltd
- Koninklijke Philips N.V.
- Thermo Fisher Scientific, Inc.
- Telix Pharmaceuticals Limited
- ABX advanced biochemical compounds GmbH
Methodology
LOADING...
